A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer

Lung Cancer

Volumn 40, Issue 3, 2003, Pages 295-299

  Scott, Hazel R ^a   McMillan, Donald C ^b   Brown, Duncan J F ^c   Forrest, Lynn M ^b   McArdle, Colin S ^b   Milroy, Robert ^c  

^a WISHAW GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c STOBHILL HOSPITAL   (United Kingdom)

Author keywords

C reactive protein; Inoperable non small cell lung cancer; Performance status; Quality of life; Weight loss

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FATIGUE; FEMALE; HUMAN; INFLAMMATION; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SYMPTOM; WEIGHT REDUCTION;

EID: 0038359755     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00077-1     Document Type: Article

References (16)

1. Ovesen L., Hannibal J., Mortensen E.L. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr. Cancer. 19:1993;159-167.
2. Simons J.P., Aaronson N.K., Vansteenkiste J.F., et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J. Clin. Oncol. 14:1996;1077-1084.
3. O'Gorman P., McMillan D.C., McArdle C.S. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr. Cancer. 32:1998;76-80.
4. O'Gorman P., McMillan D.C., McArdle C.S. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr. Cancer. 35:1999;127-129.
5. Barber M.D., Ross J.A., Fearon K.C. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr. Cancer. 35:1999;106-110.
6. Staal-van den Brekel A.J., Dentener M.A., Schols A.M., Buurman W.A., Wouters E.F. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. 13:(10):1995;2600-2605.
7. Scott H.R., McMillan D.C., Forrest L.M., Brown D.J.F., McArdle C.S., Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer. 87:2002;264-267.
8. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl 4):1991;225s-233s.
9. Mor V., Laliberte L., Morris J.N., Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 53:1984;2002-2007.
10. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:1993;365-376.
11. McMillan D.C., Scott H.R., Watson W.S., Preston T., Milroy R., McArdle C.S. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr. Cancer. 31:1998;101-105.
12. McMillan D.C., Watson W.S., O'Gorman P., Preston T., Scott H.R., McArdle C.S. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr. Cancer. 39:2001;210-213.
13. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 4:1986;702-709.
14. Scott H.R., McMillan D.C., Crilly A., McArdle C.S., Milroy R. The relationship between weight loss and interleukin-6 in non-small cell lung cancer. Br. J. Cancer. 73:1996;1560-1562.
15. Sosman J.A., Aronson F.R., Sznol M., et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin. Cancer Res. 3:1997;39-46.
16. Stone P., Hardy J., Broadley K., Tookman A.J., Kurowska A., A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br. J. Cancer. 79:1999;1479-1486.